Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B
| Autor: | Ching-Lung Lai, Jules L. Dienstag, Mark Atkins, Nancy Leung, Christine M. Hunt, Mary Woessner, Lynn D. Condreay, Richard Boehme, Eugene R. Schiff, Nathaniel A. Brown |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty Hepatitis B virus medicine.disease_cause Gastroenterology Antiviral Agents Hepatitis B Chronic Orthohepadnavirus Internal medicine Drug Resistance Viral medicine Prevalence Humans Hepatitis B e Antigens biology Reverse-transcriptase inhibitor business.industry Lamivudine Alanine Transaminase Hepatitis B biology.organism_classification medicine.disease digestive system diseases Infectious Diseases Alanine transaminase Hepadnaviridae Immunology DNA Viral biology.protein Viral disease business medicine.drug |
| Zdroj: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 36(6) |
| ISSN: | 1537-6591 |
| Popis: | YMDD variants of hepatitis B virus (HBV) emerge in some patients with chronic hepatitis B who receive lamivudine. YMDD variants were examined in 794 patients in 4 controlled studies of 1 year's duration. The long-term effects of YMDD variants were examined in a subset of patients treated up to 4 years. YMDD variants were detected by polymerase chain reaction (PCR) and restriction fragment-length polymorphism assays. After 1 year, YMDD variants were detected in 81 (24%) of 335 patients. In these patients, the median serum HBV DNA concentration at 1 year was |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|